Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

For the current quarter ending in September, Abbott expects its per-share earnings to range from $1.28 to $1.32. The company ...

Shares of Abbott Laboratories (NYSE:ABT) lost ~5% in the premarket on Thursday after the MedTech company provided its ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock ...

For traders who focus on events, examining the historical reactions of the stock to earnings announcements can offer useful ...

Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%.

Abbott Laboratories reported second-quarter earnings that slightly exceeded analyst expectations, but shares fell 2.5% following the results.

Abbott second-quarter results came in ahead of the consensus forecast, with its Medical Device business growing 13.4%.

Q2 2025 Results Conference Call July 17, 2025 9:00 AM ETCompany ParticipantsMichael Comilla - Vice President of ...